News and FDA Updates for Echo (OTC:ECTE), Impax (NASDAQ:IPXL), IPC (Nasdaq:IPCM)

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 11/24/09, Echo Therapeutics, Inc. (OTC:ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the 13th Annual Biotech and Specialty Pharmaceuticals Conference, sponsored by the New York Society of Securities Analysts, at 2:05 on December 1, 2009.

On 11/24/09, Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc. (NASDAQ:IPXL), announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

On 11/24/09, IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national hospitalist physician group practice company, announced Philip Vaidyan, M.D., FACP, an IPC hospitalist, was named by ACP Hospitalist as one of the 2009 Top Ten Hospitalists in the nation. He was recognized in the November 2009 issue of the magazine.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters´ expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company´s behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.